Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Summary

This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as denosumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2015-11-21

Primary completion

2019-12-31

Completion

2023-12-31

Drugs

Indications